AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02984982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02984982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02984982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02984982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02984982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01204710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)
Study NCT01204710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)
Study NCT01204710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg orally (PO) twice daily (BID) on each day
Study NCT01204710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally (PO) twice daily (BID) on each day
Study NCT04592120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coalition Check-Up
Description: The Coalition Check-Up identifies and addresses coalition and implementation capacity deficiencies that frequently lead to failure, following recommendations from the audit and feedback literature.
Study NCT04141059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligopin
Description: Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.
Study NCT04141059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate
Study NCT04385550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsule
Description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Study NCT04385550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105 injection
Description: AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
Study NCT04385550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.
Study NCT04385550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel injection
Description: Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.
Study NCT03537547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GeneSight Psychotropic test
Description: GeneSight Psychotropic test, developed by AssureRx Health, is a genetic test that analyses pre-selected pharmacokinetics and pharmacodynamics genes and results in a composite phenotype and interpretive report, addressing both safety and efficacy of psychiatric medications.
Study NCT03537547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-approved antidepressant or antipsychotic treatment
Description: Participant is treated with medications included in the GeneSight Psychotropic product.
Study NCT03537547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA-approved antidepressant or antipsychotic treatment
Description: Participant is treated with medications included in the GeneSight Psychotropic product.
Study NCT04228926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKY001 eye drops 0.3g:0.006mg
Description: ZKY001 eye drops of 0.002% continuously for up to 14±2 days after Corneal endothelial transplantation
Study NCT04228926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKY001 eye drops 0.3g:0.012mg
Description: ZKY001 eye drops of 0.004% continuously for up to 14±2 days after Corneal endothelial transplantation
Study NCT04228926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZKY001 simulated eye drops
Description: ZKY001 simulated eye drops continuously for up to 14±2 days after Corneal endothelial transplantation
Study NCT00151632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.
Study NCT00151632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12.
Study NCT00151632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12.
Study NCT00738894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Septal Occluder Device
Description: PFO closure with study septal occluder device
Study NCT00738894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Medical Therapy
Description: Investigator's choice of one of three regimen options specified in protocol
Study NCT00738894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet Medical Therapy
Description: Investigator's choice of one of three regimen options specified in protocol
Study NCT03901482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Study NCT03901482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo for STS101
Study NCT01382277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg per day for 76 weeks
Study NCT03878992 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Genotropin miniquick 0.5 mg, injection
Description: GH will be given as an injection. Muscle biopsy will be obtained from m. vests laterals of the dominant leg. Fat biopsies will be obtained from subcutaneous abdominal fat. Tracers will be given as a bolus followed by continuous infusion for 6 hours. For palmitate tracer the infusion will be for only 1,5 hours followed by a one hour break and then another 1 hour infusion. Blood tests will be drawn from a venous catheter placed on the dorsal side of the hand.
Study NCT02149953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine Intake
Description: Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study NCT03849677 — intervention group
Intervention type: OTHER
Intervention: Endothelial function and inflammation
Description: Analysis of endothelial function, oxidative stress
Study NCT03857997 — intervention group
Intervention type: BIOLOGICAL
Intervention: Patient blood sampling
Description: sequencing by WGS and RNA-seq
Study NCT03857997 — intervention group
Intervention type: BIOLOGICAL
Intervention: Parents blood sampling
Description: sequencing by WGS
Study NCT01373151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMS-945429 Placebo
Description: Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
Study NCT01373151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
Study NCT01373151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
Study NCT01373151 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BMS-945429
Description: Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
Study NCT01373151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
Study NCT01373151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-945429
Description: Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
Study NCT01373151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
Study NCT01373151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, 48 weeks
Study NCT01373151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, 48 weeks
Study NCT01373151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Placebo
Description: Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
Study NCT01373151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
Study NCT01373151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab Placebo
Description: Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Study NCT03309449 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intranasal mucosal atomization device
Description: Intranasal atomizer administration of simulated naloxone
Study NCT03309449 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal spray
Description: Nasal spray administration of simulated naloxone
Study NCT02837822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulator
Description: Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.
Study NCT02837822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a spinal cord stimulator
Description: The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.
Study NCT00665041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quinagolide
Description: • Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral.
Study NCT00665041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinagolide
Description: • Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral.
Study NCT02565420 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will be administered normal saline for intraoperative fluid management.
Study NCT02565420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
Study NCT04371809 — intervention group
Intervention type: OTHER
Intervention: DNA methylome
Description: Epigenomics tools combined with bioinformatic analysis to find and correlate putative useful clinical biomarkers with clinical features
Study NCT02984982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02984982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelets
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral
Study NCT02984982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelets
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral
Study NCT02984982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral
Study NCT02984982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulants
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral
Study NCT02481050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.
Study NCT03398473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira SDV
Description: Epoetin Hospira Single Dose Vial
Study NCT03398473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira MDV
Description: Epoetin Hospira Multi-Dose Vial
Study NCT00185315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventavis (Iloprost, BAYQ6256)
Description: Inhaled iloprost
Study NCT00683423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-741672
Description: Tablets, Oral, 100 mg, once daily, 3 weeks
Study NCT00683423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
Study NCT04632004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Invitation to participate
Description: Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within our survey study. Study participation has no effect on any medical treatment.
Study NCT04997603 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Accelerometer
Description: Fitbit brand
Study NCT04051541 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Agitated saline push
Description: Push of agitated saline to simulate adenosine used for supraventricular tachycardia
Study NCT04036487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthesia is maintained by desflurane in an oxygen air mixture of 60/40%. If inadequate depth of anesthesia is observed, the end-expiratory concentration of desflurane would be increased.
Study NCT04036487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia is maintained by propofol 100-200 μg/kg/min. If inadequate depth of anesthesia is observed, the rate of propofol infusion would be increased.
Study NCT01229878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (Vitamin D)
Description: 50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
Study NCT01229878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol (Vitamin D)
Description: 50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
Study NCT01155817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 200, 400, 800, oral
Study NCT00452439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actonel (Risedronate)
Description: 35 mg (pill) by mouth weekly
Study NCT00452439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: 500 mg by mouth twice a day for a total of 24 months.
Study NCT00452439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: 500 mg by mouth twice a day for a total of 24 months.
Study NCT00452439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 400 IU by mouth twice a day for a total of 24 months.
Study NCT00452439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: 400 IU by mouth twice a day for a total of 24 months.
Study NCT03031340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
Study NCT03031340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01103323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: 160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Study NCT01103323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Study NCT01103323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
Study NCT01103323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
Study NCT00086190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.
Study NCT00086190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.
Study NCT00086190 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study NCT01458067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: Oral capsules
Study NCT02778217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Culture media renwal
Study NCT03019484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding support
Description: Self-efficacy
Study NCT01265498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: obeticholic acid
Description: 25 mg daily for 72 weeks
Study NCT01265498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule, 25 mg daily for 72 weeks
Study NCT02903446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
Study NCT03902613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Participant will have an open label trial of lurasidone for eight weeks.
Study NCT00101244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV
Study NCT00101244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00101244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04621799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Description: The intra-annular delivery of non-autologous fibrin into the annulus